ANCHIANO THERAP/S’s (NASDAQ:ANCN) lock-up period will end on Monday, August 12th. ANCHIANO THERAP/S had issued 2,652,174 shares in its initial public offering on February 12th. The total size of the offering was $30,500,001 based on an initial share price of $11.50. After the expiration of ANCHIANO THERAP/S’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

A number of analysts recently issued reports on the company. ValuEngine upgraded ANCHIANO THERAP/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Robert W. Baird assumed coverage on ANCHIANO THERAP/S in a research note on Tuesday, May 28th. They set an “outperform” rating and a $12.00 price objective on the stock. Finally, Zacks Investment Research upgraded ANCHIANO THERAP/S from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a research note on Friday. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $10.42.

NASDAQ:ANCN opened at $2.69 on Monday. ANCHIANO THERAP/S has a 52-week low of $2.53 and a 52-week high of $11.50. The company has a market cap of $20.85 million and a price-to-earnings ratio of -0.51. The company’s fifty day moving average is $4.02.

ANCHIANO THERAP/S (NASDAQ:ANCN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.11. As a group, equities analysts forecast that ANCHIANO THERAP/S will post -1.94 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in ANCN. Delek Group Ltd. bought a new stake in shares of ANCHIANO THERAP/S during the 1st quarter valued at $176,000. Meitav Dash Investments Ltd. bought a new stake in shares of ANCHIANO THERAP/S during the 1st quarter valued at $177,000. FMR LLC bought a new stake in shares of ANCHIANO THERAP/S during the 1st quarter valued at $288,000. Finally, Kennedy Capital Management Inc. bought a new stake in shares of ANCHIANO THERAP/S during the 1st quarter valued at $1,359,000. Institutional investors own 6.18% of the company’s stock.

About ANCHIANO THERAP/S

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.

Recommended Story: What Does a Sell-Side Analyst Rating Mean?

Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.